The Added Power of Synthetic Control Groups: Challenging Conventional Wisdom and Trial Design in Idiopathic Pulmonary Fibrosis Research
Am J Respir Crit Care Med
.
2023 Sep 1;208(5):515-516.
doi: 10.1164/rccm.202307-1174ED.
Authors
Timothy M Dempsey
1
2
,
Andrew H Limper
3
Affiliations
1
David Grant Medical Center U.S. Air Force Travis Air Force Base, California.
2
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Mayo Clinic Rochester, Minnesota.
3
Department of Pulmonary and Critical Care Medicine Mayo Clinic Rochester, Minnesota.
PMID:
37499091
PMCID:
PMC10492256
DOI:
10.1164/rccm.202307-1174ED
No abstract available
Publication types
Editorial
Comment
MeSH terms
Control Groups
Humans
Idiopathic Pulmonary Fibrosis* / drug therapy
Pyridones
Substances
Pyridones